Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

AI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions

16 de noviembre de 2026 actualizado por: Yuqi Fang, Nanjing University

Effect of Displaying Predicted Consequences of AI Treatment Recommendations on Clinicians' Fluid and Vasopressor Decisions in Sepsis: A Randomized Crossover Study

When artificial intelligence (AI) recommends a treatment, clinicians must decide whether to follow it. This study tests whether showing the predicted consequences of a recommendation, in addition to the recommendation itself, helps clinicians accept appropriate advice and reject inappropriate advice.

We developed a clinician-anchored counterfactual model that compares the on-duty clinician's intravenous fluid and vasopressor plan with alternative plans for patients with sepsis. It predicts the patient's course under each plan and recommends a change only when the predicted benefit holds across several plausible assumptions about unrecorded factors; otherwise it states that the evidence is insufficient to recommend a change.

About 72 physicians from two hospitals, stratified by seniority, will review 30 retrospective, de-identified ICU decision points from patients with sepsis. In stage 1, each physician independently specifies fluid and vasopressor doses without any AI information. In stage 2, the same cases are reviewed under three conditions assigned by counterbalanced sequences: the case with the on-duty clinician's plan and no AI (B0); B0 plus the AI recommendation (B1); and B1 plus the predicted consequences of the on-duty and recommended plans (B2). The AI recommendation is identical in B1 and B2. Decision quality is assessed against plans made independently by expert intensivists. No patients are enrolled, and participants' decisions do not affect patient care.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Cases. Thirty decision points were selected from retrospective, de-identified ICU records before the experiment. Sampling was stratified so that the set includes AI recommendations to change treatment and to keep the current plan, both appropriate and inappropriate according to the expert reference. Each patient contributes one decision point, and none of the cases were used to develop the AI system.

Expert reference. A panel of intensivists who did not take part in AI development or in the experiment independently specify a fluid and vasopressor plan for every case, without AI output and without knowledge of study conditions. A participant's plan is scored by the number of dose levels by which it lies outside the range of expert plans (0 if within the range), summed over the two drugs. AI recommendations are classified as appropriate or inappropriate by the same rule before participant data are analyzed.

Analysis. Outcomes are analyzed with mixed-effects models with physician and case as crossed random effects. Secondary outcomes are tested in a prespecified order after the primary outcome to control the overall type I error.

Related non-interventional components. A retrospective comparison of clinicians' and the AI's plans and a prospective shadow deployment, in which the system ran on live ICU data without influencing treatment, are reported alongside this experiment but are not part of the randomized comparison.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

72

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Porcelana, 400016
        • Reclutamiento
        • The First Affiliated Hospital of Chongqing Medical University
        • Contacto:
    • Sichuan
      • Luzhou, Sichuan, Porcelana, 646000
        • Reclutamiento
        • The Affiliated Hospital of Southwest Medical University
        • Contacto:
          • Muchan Tao
          • Número de teléfono: +86 18980918483
          • Correo electrónico: mooochann@163.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Licensed physicians in critical care, emergency medicine, anaesthesiology, or respiratory medicine.
  • Currently treating ICU patients.
  • Able to complete the online questionnaire.

Exclusion Criteria:

  • Involvement in developing or evaluating the AI system, or in case selection
  • Membership of the expert reference panel
  • Participation in the pilot survey

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Sequence A

Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version A): cases 1-10 under B0, cases 11-20 under B1, cases 21-30 under B2.

Participants review the case together with the on-duty clinician's actual intravenous fluid rate and vasopressor dose and submit a final plan. No AI information is shown. This condition controls for the effect of a second review.

As B0, plus the AI output: either a recommended dose level for intravenous fluid and for vasopressor, shown with the corresponding dose range, or a statement that the evidence is insufficient to recommend a change.

As B1, with identical AI output, plus the model's predicted mean arterial pressure, lactate and urine output over the next 4 hours under the on-duty plan and under the recommended plan, shown as point estimates.

Experimental: Sequence B

Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version B): cases 1-10 under B1, cases 11-20 under B2, cases 21-30 under B0.

Participants review the case together with the on-duty clinician's actual intravenous fluid rate and vasopressor dose and submit a final plan. No AI information is shown. This condition controls for the effect of a second review.

As B0, plus the AI output: either a recommended dose level for intravenous fluid and for vasopressor, shown with the corresponding dose range, or a statement that the evidence is insufficient to recommend a change.

As B1, with identical AI output, plus the model's predicted mean arterial pressure, lactate and urine output over the next 4 hours under the on-duty plan and under the recommended plan, shown as point estimates.

Experimental: Sequence C

Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version C): cases 1-10 under B2, cases 11-20 under B0, cases 21-30 under B1.

Participants review the case together with the on-duty clinician's actual intravenous fluid rate and vasopressor dose and submit a final plan. No AI information is shown. This condition controls for the effect of a second review.

As B0, plus the AI output: either a recommended dose level for intravenous fluid and for vasopressor, shown with the corresponding dose range, or a statement that the evidence is insufficient to recommend a change.

As B1, with identical AI output, plus the model's predicted mean arterial pressure, lactate and urine output over the next 4 hours under the on-duty plan and under the recommended plan, shown as point estimates.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Distance of final treatment decisions from the range of expert plans, B2 versus B1
Periodo de tiempo: At completion of the participant's stage-2 review (single online session, approximately 2 hours)

For each case, the number of dose levels by which the participant's final fluid and vasopressor plan lies outside the range of plans made independently by the expert panel (0 = within range), summed over the two drugs. Compared between B2 and B1 with a mixed-effects model with physician and case as crossed random effects, adjusted for stage-1 score, block position and sequence.

At completion of the participant's stage-2 review (single online session, approximately 2 hours)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Discrimination between appropriate and inappropriate AI recommendations, B2 versus B1
Periodo de tiempo: At completion of the participant's stage-2 review (single online session, approximately 2 hours)

Among cases in which the AI recommends changing treatment, acceptance is defined as a final plan equal to the AI-recommended dose level for the changed drug. The outcome is the interaction between condition (B2 vs B1) and recommendation appropriateness (classified by the expert-range rule before analysis) on acceptance, estimated with a mixed-effects probit model with physician and case as crossed random effects.

At completion of the participant's stage-2 review (single online session, approximately 2 hours)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de noviembre de 2026

Finalización primaria (Estimado)

1 de diciembre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

16 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • KY2026132

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

De-identified participant-level responses (treatment decisions, confidence, response times, condition assignments and participant characteristics without identifiers) will be shared. Patient case material derived from source databases will be shared only as permitted by their data use agreements.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .